Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

FDA Repeats Birth-Defect Risk With Roche, Novartis Transplant Drugs

May 16 2008

• By Randall Osborne

Related Content

Roche’s CellCept Gains “Black Box” Warning On Use During Pregnancy

Oct 30 2007

Novartis’ Myfortic Can Increase Risk Of Fetal Damage, FDA Finds

Nov 28 2007

Tysabri Production Continues Ahead Of Possible Reintroduction

Mar 16 2005

Additional Topics

BioPharmaceutical

More from Archive

More from Pink Sheet

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window